Canadian drug patent bill
Executive Summary
Amendments to Canada's Patent Act, introduced in the House of Commons Nov. 6, would prevent market entrance of generic drugs until seven years after a patent is issued for the brandname drug. The language of the bill is almost identical to draft legislation announced in June ("The Pink Sheet" July 7, T&G-3). The amendments would allow for marketing exclusivity to be reduced or eliminated four years after the exclusivity provisions go into effect -- if an independent drug price review board determines that a drug is being sold at an excessive price.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.